Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma

Rita C. Akumuo, Anthony M. Villano, Sai P. Reddy, Karthik Devarajan, Dany Barrak, Sanjay S. Reddy

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Background: Tumor fibrosis after neoadjuvant treatment (NAT) for pancreatic ductal adenocarcinoma (PDAC) correlates with treatment response. Herein we assessed how different NAT strategies influence pathologic responses and survival. Methods: Patients with surgically resected PDAC who received NAT (1991–2020) were included. Descriptive statistics compared outcomes amongst fibrosis groups (none, minor <50 ​%, partial 51%–94 ​%, major ≥95 ​%) and NAT (chemotherapy alone, chemoradiation, or chemotherapy ​+ ​chemoradiation (total neoadjuvant therapy, TNT)). Results: Patients with major fibrosis most often received TNT (65.8 ​%, p ​< ​0.001). Major fibrosis was associated with the greatest rate of downstaging (77.8 ​%, p ​< ​0.001), highest R0 margin rate (100 ​%, p ​< ​0.01), and lowest mean positive lymph node ratio (0.80, p ​< ​0.01). Amongst complete responders, 11/14 (78.6 ​%) received TNT. Median overall (66.3 months, p ​= ​0.003) and disease-free (54.7months, p ​= ​0.05) survival were highest with major fibrosis. Conclusions: Major fibrosis and complete pathologic responses after NAT are most frequent with a TNT strategy and are associated with improved outcomes.

Original languageEnglish
Pages (from-to)9-14
Number of pages6
JournalAmerican Journal of Surgery
Volume232
Early online dateOct 8 2023
DOIs
StateE-pub ahead of print - Oct 8 2023

Keywords

  • Fibrosis
  • Neoadjuvant
  • Pancreatic cancer

Fingerprint

Dive into the research topics of 'Type of neoadjuvant treatment strategy is associated with differential pathologic responses in pancreatic ductal adenocarcinoma'. Together they form a unique fingerprint.

Cite this